Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab for Acute Uncomplicated Vaso-Occlusive Episodes in SCD
NCT04912869Phase 1Completed
- Sponsor
- Roche
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 1, randomised, double-blind trial in sickle cell disease (SCD) comparing Crovalimab with Placebo (2 arms). Primary endpoints: Percentage of Participants With Adverse Events at Day 84 and Percentage of Participants with Infusion-Related Reactions and Hypersensitivity at Day 84. Started Mar 2022; status: completed.
02
Drugs
crovalimab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04912869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04912869.